Y Intercept Hong Kong Ltd Purchases New Position in Sera Prognostics, Inc. $SERA

Y Intercept Hong Kong Ltd acquired a new stake in Sera Prognostics, Inc. (NASDAQ:SERA) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 67,692 shares of the company’s stock, valued at approximately $188,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of SERA. Abel Hall LLC acquired a new stake in shares of Sera Prognostics in the second quarter valued at about $31,000. Wagner Wealth Management LLC purchased a new position in Sera Prognostics in the 2nd quarter worth approximately $34,000. XTX Topco Ltd acquired a new stake in Sera Prognostics in the first quarter valued at approximately $39,000. Nuveen LLC acquired a new stake in Sera Prognostics in the first quarter valued at approximately $138,000. Finally, Cliftonlarsonallen Wealth Advisors LLC purchased a new stake in shares of Sera Prognostics during the second quarter valued at approximately $218,000. Institutional investors and hedge funds own 54.64% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently commented on SERA. Wall Street Zen raised shares of Sera Prognostics from a “sell” rating to a “hold” rating in a research report on Saturday, October 25th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Sera Prognostics in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, Sera Prognostics currently has a consensus rating of “Sell”.

Sera Prognostics Stock Down 6.7%

Shares of SERA opened at $2.52 on Monday. The business’s 50 day moving average is $3.20 and its two-hundred day moving average is $2.69. Sera Prognostics, Inc. has a 52-week low of $1.37 and a 52-week high of $9.13. The firm has a market cap of $94.93 million, a price-to-earnings ratio of -2.96 and a beta of 0.97.

Insider Activity

In related news, CEO Zhenya Lindgardt sold 21,158 shares of the company’s stock in a transaction on Tuesday, September 9th. The shares were sold at an average price of $3.15, for a total value of $66,647.70. Following the sale, the chief executive officer directly owned 811,136 shares of the company’s stock, valued at $2,555,078.40. This represents a 2.54% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders have sold a total of 52,627 shares of company stock valued at $159,853 in the last three months. 15.80% of the stock is currently owned by insiders.

Sera Prognostics Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.